Breaking News

Sterling Makes Strategic Investment in ADC Bio

Will work together to develop an integrated service offering combining ADC Bio’s expertise with Sterling’s high potency small molecule expertise.

By: Contract Pharma

Contract Pharma Staff

Sterling Pharma Solutions, a global CDMO, has entered a new strategic partnership with ADC Biotechnology, a UK company specializing in antibody drug conjugates. Sterling will make a significant investment in the business with plans to acquire ADC Biotechnology in 1Q21. The businesses will work together to develop an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise. Kevin Cook, CEO...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters